2.6.3.3 NCCTG Statistical Data Center The NCCTG Statistical Data Center (SDC), under the direction of the Group Statistician, Daniel J. Sargent, Ph.D., is comprised of two units: the Statistics Unit and the Data Systems Unit. The two units function in a highly coordinated fashion under the leadership of Dr. Sargent and the Group Operations Coordinator. Together, these two units provide statistical collaboration, data management support, and information technology (IT) support for the development and conduct of NCCTG cancer clinical trials, including translational research. The Statistics Unit exists within the Mayo Clinic Cancer Center (MCCC) Biostatistics Shared Resource, also directed by Dr. Sargent, where statistical support for multiple programs provides synergies that benefit all. There are over 40 individuals currently in this shared resource. The NCCTG Statistics Unit currently consists of portions of 8 Ph.D statisticians, 9 master trained statisticians, 10 statistical programmer analysts (SPAs).and 2 administrative assistants. The Data Systems Unit, under the direction of Ms. Paulson, exists within the MCCC Clinical Research Office Shared Resource that includes over 140 individuals. Again, the high degree of interaction provides synergies that benefit all. The NCCTG Data Systems Unit is comprised of three subgroups: 1. Programming Unit with 17 Analyst/Programmers. 2. Data Coordination Unit with 4 Data Management Specialists and 1 Administrative Assistant. 3. Clinical Trials Coordination that includes the Quality Control Unit, the Randomization Unit, and the Compliance Unit. The Quality Control Unit includes 18 Quality Control Specialists,'the NCCTG SAE Coordinator, the NCCTG Pathology Coordinator, the NCCTG Surgery Coordinator, and 1 supervisor. The Randomization Unit includes 3 Randomization Specialists. The Compliance Unit includes 2 Compliance Specialists. While the personnel within the Compliance Unit are considered members of the Data Systems Unit, their activities are defined by the NCCTG Audit Committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037404-24
Application #
7848123
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
24
Fiscal Year
2009
Total Cost
$2,688,485
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Foster, Jared C; Le-Rademacher, Jennifer G; Feliciano, Josephine L et al. (2017) Comparative ""nocebo effects"" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. Cancer 123:4193-4198
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Kottschade, Lisa; Novotny, Paul; Lyss, Alan et al. (2016) Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance). Support Care Cancer 24:2661-7
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Atherton, Pamela J; Burger, Kelli N; Pederson, Levi D et al. (2016) Patient-reported outcomes questionnaire compliance in Cancer Cooperative Group Trials (Alliance N0992). Clin Trials 13:612-620
Miller, Robert C; Petereit, Daniel G; Sloan, Jeff A et al. (2016) N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys 95:1168-74

Showing the most recent 10 out of 377 publications